A large meta-analysis, published in Diabetology & Metabolic Syndrome, suggested that semaglutide improved several liver-related and metabolic outcomes in people with or at risk of developing MASH, ...
A new analysis of the SELECT trial – the largest and longest clinical trial to date examining the cardiovascular benefits of semaglutide (a medication used to support weight loss and diabetes ...
Everyday Health on MSN
The pros, cons, and considerations of taking Ozempic or other drugs for weight loss
Use of the diabetes drug Ozempic for weight loss is rising. Understand the research, how it works, who should use it, and ...
Weight management medications are transforming the landscape of obesity treatment, with semaglutide emerging as a groundbreaking solution for individuals struggling with weight loss. As demand surges ...
Mediafeed on MSN
Ozempic & testosterone: Is there a link?
This article was reviewed by Lynn Marie Morski, MD, JD. Key Takeaways: Ozempic may help improve testosterone levels in people ...
Ozempic, a semaglutide drug originally developed for type-2 diabetes, has been in the news as a fast-track weight-loss ...
A detailed analysis in the Canadian Journal of Cardiology of the cost-effectiveness of semaglutide shows that with price reductions, it could meet the benchmark for healthcare value, urging ...
Patients with type 2 diabetes and a baseline HbA1c greater than 7.0% experienced greater cardiovascular benefits while using oral semaglutide. Oral semaglutide elicits more pronounced cardiovascular ...
Please provide your email address to receive an email when new articles are posted on . Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a microsimulation ...
In today’s fast-paced world, maintaining optimal health and wellness can often feel like a daunting task. With numerous products on the market, finding the right one that aligns with your health goals ...
Please provide your email address to receive an email when new articles are posted on . The GLP-1 receptor agonist semaglutide may not only add another therapeutic option for chronic kidney disease, ...
CHICAGO — Use of the GLP-1 receptor agonist semaglutide improved walking capability in patients with peripheral arterial disease (PAD) and type 2 diabetes (T2D), regardless of duration of diabetes, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results